Compare Citius Pharmaceuticals Inc (CTXR) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Home Depot Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Home Depot Inc trades at $337.71 (market cap $336.77B). The key difference: Home Depot Inc is far larger — about 23003.4× Citius Pharmaceuticals Inc's market cap, and Home Depot Inc pays a 2.76% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | HD | |
|---|---|---|
Market Cap | $14.64M | $336.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $423.42 |
52-Week Low | $0.53 | $297.51 |
Enterprise Value | $10.86M | $398.32B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Home Depot (HD) trades at $337.11, down 1.8% on the day, with a bearish technical signal and mixed earnings history. The stock shows strong profitability with a net margin of 8.41% and ROE of 128.38%, but faces margin compression and weak big-ticket demand. Recent news highlights institutional selling and concerns over rising mortgage rates impacting home improvement spending.
The outlook is cautious due to near-term headwinds, but analyst consensus remains bullish with a $370.59 price target. Risks include housing market sensitivity and competitive pressures, while opportunities lie in Pro segment growth and dividend stability. Long-term prospects depend on economic resilience and execution against margin challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
